Friday, July 12, 2024 1:25:42 PM
LessIsMore,
You are wrong!; ). Try looking at 2017 and 2020 for total length of time shares were available at those prices and below. Then go back and check when I posted that the share price could possibly drop to as low as $.05 before a turnaround.
The damage done to shareholders is by the manipulators and their supporters/advocates not by someone who has been supporting NWBO through “the process” of bringing a breakthrough technology that offers a pathway to a cure for cancer patients and beyond and has stated from the beginning that they would be in to the end. Besides the worst damage will be when folks are short and desperately trying to buy the shares that I and other longs won’t sell. This is especially true if several big market makers are removed from the picture by inability to have access to making a market in NWBO shares which would help reduce liquidity at a critical time for them ; ). Best wishes.
You are wrong!; ). Try looking at 2017 and 2020 for total length of time shares were available at those prices and below. Then go back and check when I posted that the share price could possibly drop to as low as $.05 before a turnaround.
The damage done to shareholders is by the manipulators and their supporters/advocates not by someone who has been supporting NWBO through “the process” of bringing a breakthrough technology that offers a pathway to a cure for cancer patients and beyond and has stated from the beginning that they would be in to the end. Besides the worst damage will be when folks are short and desperately trying to buy the shares that I and other longs won’t sell. This is especially true if several big market makers are removed from the picture by inability to have access to making a market in NWBO shares which would help reduce liquidity at a critical time for them ; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
